Cargando…
Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia
Aim. To examine the potential value of previously identified biomarkers using proteomics in early screening for preeclampsia (PE). Methods. 24 blood samples from women who subsequently developed PE and 48 from uncomplicated pregnancies were obtained at 11–13 weeks and analysed after delivery. Cystat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299787/ https://www.ncbi.nlm.nih.gov/pubmed/25628472 http://dx.doi.org/10.1155/2015/121848 |
_version_ | 1782353438986731520 |
---|---|
author | Kolialexi, Aggeliki Gourgiotis, Dimitrios Daskalakis, George Marmarinos, Antonis Lykoudi, Alexandra Mavreli, Danai Mavrou, Ariadni Papantoniou, Nikolas |
author_facet | Kolialexi, Aggeliki Gourgiotis, Dimitrios Daskalakis, George Marmarinos, Antonis Lykoudi, Alexandra Mavreli, Danai Mavrou, Ariadni Papantoniou, Nikolas |
author_sort | Kolialexi, Aggeliki |
collection | PubMed |
description | Aim. To examine the potential value of previously identified biomarkers using proteomics in early screening for preeclampsia (PE). Methods. 24 blood samples from women who subsequently developed PE and 48 from uncomplicated pregnancies were obtained at 11–13 weeks and analysed after delivery. Cystatin-C, sVCAM-1, and Pappalysin-1 were quantified by ELISA. Maternal characteristics and medical history were recorded. Results. Median values of Cystatin-C, sVCAM-1, and Pappalysin-1 in the PE group as compared to controls were 909.1 gEq/mL versus 480.0 gEq/mL, P = .000, 832.0 gEq/mL versus 738.8 gEq/mL, P = .024, and 234.4 gEq/mL versus 74.9 gEq/mL, P = .064, respectively. Areas under the receiver-operating characteristic curves (AUC, standard error (SE)) for predicting PE were Cystatin-C: 0.90 (SE 0.04), VCAM-1: 0.66 (SE 0.074), and Pappalysin-1: 0.63 (SE 0.083). To discriminate between cases at risk for PE and normal controls, cut-off values of 546.8 gEq/mL for Cystatin-C, 1059.5 gEq/mL for sVCAM-1, and 220.8 gEq/mL for Pappalysin-1 were chosen, providing sensitivity of 91%, 41%, and 54% and specificity of 85%, 100%, and 95%, respectively. Conclusions. sVCAM-1 and Pappalysin-1 do not improve early screening for PE. Cystatin-C, however, seems to be associated with subsequent PE development, but larger studies are necessary to validate these findings. |
format | Online Article Text |
id | pubmed-4299787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-42997872015-01-27 Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia Kolialexi, Aggeliki Gourgiotis, Dimitrios Daskalakis, George Marmarinos, Antonis Lykoudi, Alexandra Mavreli, Danai Mavrou, Ariadni Papantoniou, Nikolas Dis Markers Research Article Aim. To examine the potential value of previously identified biomarkers using proteomics in early screening for preeclampsia (PE). Methods. 24 blood samples from women who subsequently developed PE and 48 from uncomplicated pregnancies were obtained at 11–13 weeks and analysed after delivery. Cystatin-C, sVCAM-1, and Pappalysin-1 were quantified by ELISA. Maternal characteristics and medical history were recorded. Results. Median values of Cystatin-C, sVCAM-1, and Pappalysin-1 in the PE group as compared to controls were 909.1 gEq/mL versus 480.0 gEq/mL, P = .000, 832.0 gEq/mL versus 738.8 gEq/mL, P = .024, and 234.4 gEq/mL versus 74.9 gEq/mL, P = .064, respectively. Areas under the receiver-operating characteristic curves (AUC, standard error (SE)) for predicting PE were Cystatin-C: 0.90 (SE 0.04), VCAM-1: 0.66 (SE 0.074), and Pappalysin-1: 0.63 (SE 0.083). To discriminate between cases at risk for PE and normal controls, cut-off values of 546.8 gEq/mL for Cystatin-C, 1059.5 gEq/mL for sVCAM-1, and 220.8 gEq/mL for Pappalysin-1 were chosen, providing sensitivity of 91%, 41%, and 54% and specificity of 85%, 100%, and 95%, respectively. Conclusions. sVCAM-1 and Pappalysin-1 do not improve early screening for PE. Cystatin-C, however, seems to be associated with subsequent PE development, but larger studies are necessary to validate these findings. Hindawi Publishing Corporation 2015 2015-01-05 /pmc/articles/PMC4299787/ /pubmed/25628472 http://dx.doi.org/10.1155/2015/121848 Text en Copyright © 2015 Aggeliki Kolialexi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kolialexi, Aggeliki Gourgiotis, Dimitrios Daskalakis, George Marmarinos, Antonis Lykoudi, Alexandra Mavreli, Danai Mavrou, Ariadni Papantoniou, Nikolas Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia |
title | Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia |
title_full | Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia |
title_fullStr | Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia |
title_full_unstemmed | Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia |
title_short | Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia |
title_sort | validation of serum biomarkers derived from proteomic analysis for the early screening of preeclampsia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299787/ https://www.ncbi.nlm.nih.gov/pubmed/25628472 http://dx.doi.org/10.1155/2015/121848 |
work_keys_str_mv | AT kolialexiaggeliki validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia AT gourgiotisdimitrios validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia AT daskalakisgeorge validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia AT marmarinosantonis validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia AT lykoudialexandra validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia AT mavrelidanai validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia AT mavrouariadni validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia AT papantoniounikolas validationofserumbiomarkersderivedfromproteomicanalysisfortheearlyscreeningofpreeclampsia |